Order Summary

In order to access content on the Celltelligence Library, you must have an account.

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information Already have an account? Log in here


By selecting this, I agree to receive emails from celltelligence.com.

You will be granted access to your Celltelligence Library to view the full article after sign up.

Thoughts on Breyanzi’s sNDA Acceptance in Japan for 2L LBCL

Here is a brief preview of this blast: BMS recently announced (press release) that Japan’s Ministry of Health, Labour and Welfare (MHLW) accepted Breyanzi’s (CD19 CAR-T) sNDA in 2L LBCL. Below, Celltelligence provides insights on Breyanzi’s potential approval timeline for 2L LBCL in Japan, while discussing possible reimbursement issues as the CD19 CAR-T moves into earlier lines of therapy.

About The Author

Mark McCully, PhD

Senior Content Lead
Mark McCully, PhD is the Content Lead for Celltelligence covering the dynamic and rapidly evolving cell therapy space. Mark regularly attends large and small cell therapy scientific meetings to build upon his decade of oncology R&D experience. To that end, Mark previously worked on numerous consulting projects for large cap pharma and emerging biotech to help characterize the ever-changing landscape.